ECSP014065A - Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero - Google Patents
Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamiferoInfo
- Publication number
- ECSP014065A ECSP014065A EC2001004065A ECSP014065A ECSP014065A EC SP014065 A ECSP014065 A EC SP014065A EC 2001004065 A EC2001004065 A EC 2001004065A EC SP014065 A ECSP014065 A EC SP014065A EC SP014065 A ECSP014065 A EC SP014065A
- Authority
- EC
- Ecuador
- Prior art keywords
- cognitive dysfunction
- pharmaceutically acceptable
- disease
- agonist
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica y un procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero, que comprende la administración de un agonista parcial del receptor de nicotina o una sal farmacéuticamente aceptable del mismo; y un inhibidor de acetilcolinesterasa, un inhibidor de butilcolinesterasas, un agente estrogénico, un modulador selectivo del receptor de estrógenos o un agonista muscarínico, o una sal farmacéuticamente aceptable de los mismos; y un vehículo farmacéuticamente aceptable. El agonista parcial del receptor de nicotina y el inhibidor de acetilcolinesterasa, el inhibidor de butilcolinesterasa, el estrógeno, el modulador selectivo del receptor de estrógenos o el agonista muscarínico están presente en cantidades que hacen a la composición eficaz en la potenciación de la cognición o en el tratamiento de enfermedades de disfunción cognitiva que incluyen, pero sin limitación, la Enfermedad de Alzheimer, deterioro cognitivo leve, disminución cognitiva relacionada con la edad, demencia vascular, demencia por enfermedad de Parkinson. Enfermedad de Huntington, Apoplejía, TBI, demencia asociada con el SIDA y esquizofrenia. También se describe el procedimiento de uso de estas composiciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20279900P | 2000-05-09 | 2000-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP014065A true ECSP014065A (es) | 2003-01-13 |
Family
ID=22751325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2001004065A ECSP014065A (es) | 2000-05-09 | 2001-05-08 | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20010036949A1 (es) |
| EP (1) | EP1280554A2 (es) |
| JP (1) | JP2003532670A (es) |
| AR (1) | AR028426A1 (es) |
| AU (1) | AU2001248699A1 (es) |
| BR (1) | BR0110487A (es) |
| CA (1) | CA2409720A1 (es) |
| EC (1) | ECSP014065A (es) |
| GT (1) | GT200100075A (es) |
| MX (1) | MXPA02011051A (es) |
| PA (1) | PA8516701A1 (es) |
| PE (1) | PE20011256A1 (es) |
| PY (1) | PY0108909A (es) |
| SV (1) | SV2002000440A (es) |
| TN (1) | TNSN01068A1 (es) |
| UY (1) | UY26693A1 (es) |
| WO (1) | WO2001085145A2 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| DE60124730T2 (de) | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| CZ20032814A3 (cs) * | 2001-04-20 | 2004-08-18 | Pfizeráproductsáinc | Způsob přípravy �Ź@@substituovaných indenů a aryl@kondezovaných azapolycyklických sloučenin |
| AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
| US20040006092A1 (en) * | 2001-08-31 | 2004-01-08 | Neurochem, Inc. | Amidine derivatives for treating amyloidosis |
| AU2003270446A1 (en) * | 2002-09-25 | 2004-04-19 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating alzheimer's disease and dementias of vascular origin |
| US8030300B2 (en) * | 2003-06-10 | 2011-10-04 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| KR20140015122A (ko) | 2003-10-01 | 2014-02-06 | 아돌로 코포레이션 | 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법 |
| US20060019938A1 (en) * | 2003-12-31 | 2006-01-26 | Beer Tomasz M | Estrogen administration for treating male cognitive dysfunction or improving male cognitive function |
| US7262223B2 (en) * | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
| US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| CA2566204A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor |
| US7304171B2 (en) * | 2004-05-27 | 2007-12-04 | Migenix Corp. | Compounds and methods for cytoprotection |
| EP2275096A3 (en) * | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) * | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US7576207B2 (en) | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| GB0607952D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| WO2008033299A2 (en) | 2006-09-12 | 2008-03-20 | Adolor Corporation | Use of n-containing spirocompounds for the enhancement of cognitive function |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| US8846061B1 (en) | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
| US8349376B1 (en) | 2011-03-08 | 2013-01-08 | Bezzek Mark S | Anti-dementia regimen |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| WO2012142039A1 (en) * | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
-
2001
- 2001-01-16 US US09/760,966 patent/US20010036949A1/en not_active Abandoned
- 2001-04-23 PY PY200100108909A patent/PY0108909A/es unknown
- 2001-04-24 WO PCT/IB2001/000681 patent/WO2001085145A2/en not_active Ceased
- 2001-04-24 JP JP2001581799A patent/JP2003532670A/ja active Pending
- 2001-04-24 BR BR0110487-0A patent/BR0110487A/pt not_active IP Right Cessation
- 2001-04-24 EP EP01921733A patent/EP1280554A2/en not_active Withdrawn
- 2001-04-24 MX MXPA02011051A patent/MXPA02011051A/es unknown
- 2001-04-24 AU AU2001248699A patent/AU2001248699A1/en not_active Abandoned
- 2001-04-24 CA CA002409720A patent/CA2409720A1/en not_active Abandoned
- 2001-05-04 GT GT200100075A patent/GT200100075A/es unknown
- 2001-05-07 UY UY26693A patent/UY26693A1/es not_active Application Discontinuation
- 2001-05-08 EC EC2001004065A patent/ECSP014065A/es unknown
- 2001-05-08 AR ARP010102169A patent/AR028426A1/es unknown
- 2001-05-08 TN TNTNSN01068A patent/TNSN01068A1/fr unknown
- 2001-05-08 SV SV2001000440A patent/SV2002000440A/es not_active Application Discontinuation
- 2001-05-08 PE PE2001000412A patent/PE20011256A1/es not_active Application Discontinuation
- 2001-05-09 PA PA20018516701A patent/PA8516701A1/es unknown
-
2003
- 2003-01-21 US US10/347,955 patent/US20030130303A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PA8516701A1 (es) | 2002-09-17 |
| US20010036949A1 (en) | 2001-11-01 |
| WO2001085145A2 (en) | 2001-11-15 |
| EP1280554A2 (en) | 2003-02-05 |
| UY26693A1 (es) | 2001-12-28 |
| GT200100075A (es) | 2001-12-31 |
| CA2409720A1 (en) | 2001-11-15 |
| PY0108909A (es) | 2003-11-03 |
| WO2001085145A3 (en) | 2002-06-13 |
| US20030130303A1 (en) | 2003-07-10 |
| TNSN01068A1 (fr) | 2005-11-10 |
| AR028426A1 (es) | 2003-05-07 |
| PE20011256A1 (es) | 2001-12-29 |
| SV2002000440A (es) | 2002-10-24 |
| JP2003532670A (ja) | 2003-11-05 |
| BR0110487A (pt) | 2003-04-01 |
| AU2001248699A1 (en) | 2001-11-20 |
| WO2001085145A8 (en) | 2001-12-13 |
| MXPA02011051A (es) | 2003-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8516701A1 (es) | Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamifero | |
| DOP2002000345A (es) | Uso de agonistas inversos de gaba en combinación con agonistas parciales del receptor de nicotina, estrógeno, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| DE69017302D1 (de) | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| MA28009A1 (fr) | Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques | |
| DE60124972D1 (de) | Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung der weiblichen sexuellen Störungen | |
| DE69222500D1 (de) | Verfahren und formulierungen zur kontrazeption und zur behandlung von benignen gynäkologischen störungen | |
| NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
| EA200201000A1 (ru) | Гормон-заместительная терапия | |
| ES2187575T3 (es) | Hexapeptidos ciclicos dotados de actividad antibiotica. | |
| DE69432990D1 (de) | PROGESTAGEN-FREIE FORMULIERUNGEN VON GnRH UND ESTROGEN ZUR BEHANDLUNG VON BENIGNEN GYNÄKOLOGISCHEN STÖRUNGEN | |
| MA27863A1 (fr) | Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur | |
| ES2124225T3 (es) | Tratamiento de la disfuncion erectil. | |
| DE60130147D1 (de) | Verwendung oraler formulierungen zur behandlung der weiblichen sexuellen störung | |
| BR9509807A (pt) | Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3 | |
| AR014964A1 (es) | Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones | |
| DK1109814T3 (da) | 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion | |
| ES2189956T3 (es) | Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos. | |
| HUP0203050A2 (hu) | Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények | |
| BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
| DE50202865D1 (de) | Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| MX9207493A (es) | Composicion farmaceutica que contiene compuestos de trioxolano y diperoxido. | |
| AR004507A1 (es) | Un profarmaco de trovafloxacina, un procedimiento para tratar una in infeccion bacteriana en un mamifero mediante el mismo, un procedimiento paraprepararlo y una composicion farmaceutica que lo comprende | |
| DE60129846D1 (de) | Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems |